In this article, we will look at the 10 Stocks Under $5 with Huge Upside Potential.
On April 17, Kevin Simpson, Capital Wealth Planning founder and CIO, appeared on CNBC’s ‘Closing Bell’ to talk about his view on equities, what to expect next week, and more.
He cited the breadth of the market, stating that it’s not just the Mag 7 or tech, but also the S&P, the Dow, the Nasdaq, and even the Russell that is moving higher. He added that it was almost a sigh of relief when we got the all-clear signal with respect to the straits, but whether it is an all-clear for real or not requires a little bit more time to see if that is actually the case. However, there is enough of a foundation for this market to move higher, according to him.
READ ALSO: 8 Most Undervalued Biotech Stocks to Buy Right Now AND 8 Best Low Priced Biotech Stocks to Invest In.
Simpson further stated that he is looking at this from a standpoint of “boy, it has come really far, really fast, and where do we go from here”. Talking about what to expect next week, he stated that oil is the real linchpin, and he does not believe anything other than oil can derail this rally. According to him, oil prices could still drive equities lower.
With these broader market trends in view, let’s look at the best stocks under $5 with huge upside potential.
Our Methodology
We used the Finviz stock screener to make a list of the best stocks under $5 with huge upside potential and picked the top 10 with the highest number of hedge fund holders, as of Q4 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database.
Note: All data was recorded on April 17.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Stocks Under $5 with Huge Upside Potential
10. Keel Infrastructure Corp. (NASDAQ:KEEL)
Keel Infrastructure Corp. (NASDAQ:KEEL) is one of the best stocks under $5 with huge upside potential. Cantor Fitzgerald cut the price target on Keel Infrastructure Corp. (NASDAQ:KEEL) to $3 from $5 on April 9 and reaffirmed an Overweight rating on the shares. The firm told investors that it believes the world is heading toward the proliferation of AI across nearly every sector, business, and economy, and in this context, it sees AI infrastructure as “an attractive place to invest”. This holds especially true given that investors are somewhat agnostic to which AI app or AI model emerges victorious. Cantor also stated that it envisions a persistent supply/demand imbalance for the next five-plus years that caters to pricing remaining strong.
In a separate development, Keel Infrastructure Corp. (NASDAQ:KEEL) and Bitfarms Ltd. announced the completion of Bitfarms’ previously announced redomiciliation from Canada to the United States on April 1, following which Keel Infrastructure, a corporation formed under the laws of the State of Delaware, is now the ultimate parent corporation of Bitfarms. Management stated that Keel Infrastructure Corp. (NASDAQ:KEEL) will continue carrying on the business currently conducted by Bitfarms and its subsidiaries, and its sole principal executive office will be in New York City.
Keel Infrastructure Corp. (NASDAQ:KEEL) is involved in building AI-focused data centers and energy assets with a focus on infrastructure and energy required to support high-performance computing and artificial intelligence workloads.
9. Alvotech (NASDAQ:ALVO)
Alvotech (NASDAQ:ALVO) is one of the best stocks under $5 with huge upside potential. Alvotech (NASDAQ:ALVO) has received several rating updates from analysts since the release of its fiscal Q4 and full-year 2025 results. On March 23, Barclays cut the price target on the stock to $4 from $5 and maintained an Underweight rating on the shares. The firm told investors in a research note that it anticipates the shares to “remain in a holding pattern” pending U.S. approvals in fiscal Q4. It also stated that the company’s financial flexibility “bears watching”, given its high leverage.
The same day, UBS also cut the price target on Alvotech (NASDAQ:ALVO) to $6 from $10 while reiterating a Buy rating on the shares. It told investors in a research note that it is confident in the remediation plan outlined by the company’s management, and anticipates these approvals to occur by year-end 2026. The firm also stated that it believes the stock has largely reset after this sequence of negative developments, with expectations now meaningfully lower.
Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. The firm’s focus is on the development of its product candidates, with its operations divided into the following geographical segments: Europe, North America, Asia, and Other.
Hedge Fund Resource Center